Related Experiment Video
Updated: Feb 5, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Prophylactic lactoferrin for preventing late-onset sepsis and necrotizing enterocolitis in preterm infants: A
1Department of Neonatology, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Yuzhong China International Science and Technology Cooperation Base of Child Development and Critical Disorders Chongqing Key Laboratory of Pediatrics, Chongqing, China.
Insights
Prophylactic lactoferrin supplementation significantly reduces late-onset sepsis and necrotizing enterocolitis in preterm infants. This intervention also lowers hospital-acquired infections and infection-related mortality without adverse effects.
Area of Science:
- Neonatal Medicine
- Microbiome Research
- Immunology
Background:
- Prophylactic strategies for preterm infants' gut microbiota and immune systems are debated.
- Lactoferrin is a promising supplement, but its efficacy and safety for preventing late-onset sepsis (LOS) and necrotizing enterocolitis (NEC) remain controversial.
Purpose of the Study:
- To evaluate the effect and safety of lactoferrin supplementation in preventing LOS and NEC in preterm infants.
- To synthesize evidence from randomized controlled trials (RCTs) through meta-analysis.
Main Methods:
- Searched multiple databases (Medline, Embase, Cochrane Library, etc.) for English and Chinese RCTs.
- Included 9 RCTs involving 1834 preterm infants.
- Conducted meta-analysis using Rev Man 5.3 software with random-effects models.
Main Results:
- Lactoferrin significantly reduced the incidence of culture-proven LOS (RR 0.47) and NEC (stage II or more) (RR 0.40).
- Associated with decreased hospital-acquired infections (RR 0.47) and a trend towards reduced infection-related mortality (RR 0.24).
- Shortened time to full enteral feeding (WMD -2.11 days) with no significant effect on all-cause mortality.
Conclusions:
- Lactoferrin supplementation effectively reduces NEC and LOS incidence in preterm infants.
- It also decreases hospital-acquired infections and infection-related mortality.
- No obvious adverse effects were reported in the included trials.
Background:
Currently, prophylactic use of drugs to promote a healthy gut microbiota and immune system in preterm infants is hot debated, among which lactoferrin is a promising supplementation. However, the effect and safety of lactoferrin to prevent late-onset sepsis (LOS) and necrotizing enterocolitis (NEC) in preterm infants remains controversial.
Methods:
Databases including Medline, Ovid-Embase, The Cochrane Library, CBM, CNKI, and VIP database of Chinese Journal were searched to collect randomized controlled trials (RCTs) about lactoferrin for preventing LOS and NEC in preterm infants. Languages of included RCTs were restricted to English and Chinese. Meta-analysis was conducted by Rev Man 5.3 software. The Mantel-Haenszel method with random-effects model was used to calculate pooled relative risks (RRs) and 95% confidence intervals (CIs).
Results:
A total of 9 RCTs, involving 1834 patients, were included. Pooled analysis showed that prophylactic lactoferrin could significantly reduce the incidence all culture-proven LOS (41/629 [6.5%] vs 96/659 [15.3%]; RR 0.47; 95% CI 0.33-0.67; P < .01) and NEC (stage II or more) (9/448 [2.0%] vs 26/462 [5.6%]; RR 0.40; 95% CI 0.18-0.86; P < .01). Lactoferrin was also associated with a significantly decreased hospital-acquired infection (16/139 [11.5%] vs 35/140 [25%]; RR 0.47; 95% CI 0.27-0.80; P < .01); and infection-related mortality (4/474 [0.8%] vs 25/505 [4.9%]; RR 0.24; 95% CI 0.04-1.32; P < .01, I = 53%). Lactoferrin could shorten time to reach full enteral feeding (weighted mean difference [WMD] = -2.11, 95% CI -3.12 to -1.10; P < .01) and showed a decreasing trend of duration of hospitalization (WMD = -1.69, 95% CI -6.87 to 3.50; P < .01; I = 95%). Lactoferrin did not have a significant effect on all-cause mortality (22/625 [3.5%] vs 35/647 [5.4%]; RR 0.70; 95% CI 0.38-1.30; P = .16; I = 13%). None of the included trials reported any confirmed adverse effects caused by the supplemented lactoferrin or probiotics.
Conclusion:
Current evidence indicates that lactoferrin could significantly reduce the incidence of NEC and LOS, and decrease the risk of hospital-acquired infection and infection-related mortality in premature infants without obvious adverse effects.
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Random and Systematic Errors
Directing Effect of Substituents: meta-Directing Groups
Systematic Sampling Method
Systematic sampling is one of the simplest methods...
Cancer Prevention
Some...

